Extract

Background and study aims Adrenaline autoinjectors are prescribed for patients at risk of severe systemic allergic reactions (anaphylaxis), most commonly for children with food allergy. Several different devices are available, and patients are sometimes switched from their own device to a new one. It is unclear whether switching a patient from one device to a new one without training them in the new device means that they will be less able to effectively administer adrenaline in the event of anaphylaxis. This study is designed to answer whether 'device switches' without training in how to use the new device are potentially harmful, by decreasing patients' ability to effectively administer adrenaline for treatment of anaphylaxis. Who can participate: Participants from the MAMA research study (ISRCTN12504076) who have completed the study. What does the study involve? Assessment of whether participants are able to effectively administer adrenaline, using one of several different adrenaline autoinjector devices. What are the possible benefits and risks of participating? The benefits are possibly to understand more about severe allergic reactions and their management. The risk is that participation may be slightly stressful, since the scenario-based assessment of adrenaline autoinjector use is quite realistic. Where is the study run from? St Mary’s Hospital, Paddington and Imperial College London (UK) When is the study starting and how long is it expected to run for? March 2012 to August 2013 Who is funding the study? Lincoln Medical, a company that makes adrenaline autoinjectors Who is the main contact? Dr Robert Boyle [email protected]

Inclusion criteria

• Food allergy

Links

• isrctn
• ictrp